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Background: In 2018, Zimbabwe declared anothermajor cholera outbreak a decade after recording one of 
the worst cholera outbreaks in Africa. 
Methods: Amathematical model for cholerawas used to estimate the magnitude of the cholera outbreak 
and vaccination coverage using cholera cases reported data. A Markov chain Monte Carlo method based 
on a Bayesian framework was used to fit the model in order to estimate the basic reproductive number 
and required vaccination coverage for cholera control. 
Results: The results showed that the outbreak had a basic reproductive number of 1.82 (95% credible 
interval [CrI] 1.53–2.11) and required vaccination coverage of at least 58% (95% Crl 45–68%) to be 
contained using an oral cholera vaccine of 78% efficacy. Sensitivity analysis demonstrated that a vaccine 
with at least 55% efficacywas sufficient to contain the outbreak but at higher coverage of 75% (95% Crl 58– 
88%). However, high-efficacy vaccines would greatly reduce the required coverage, with 100% efficacy 
vaccine reducing coverage to 45% (95% Crl 35–53%). 
Conclusions: These findings reinforce the crucial need for oral cholera vaccines to control cholera in 
Zimbabwe, considering that the decay of water reticulation and sewerage infrastructure is unlikely to be 
effectively addressed in the coming years. 
©2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).          
          
         
        
         
         
          
         
        
           
Introduction 
For the second time within a decade, Zimbabwe declared a 
cholera outbreak on 11 September 2018 following the death of 20 
people from the disease and >3500 reported cases since the 
beginning of September 2018 (Chipunza, 2018). Between 2008 and 
2009, Zimbabwe recorded one of the worst cholera outbreaks in 
Africa, which resulted in 98,585 reported cases and 4287 deaths 
(Mukandavire et al., 2011). The timing of the 2018 outbreak was 
very similar to the 2008–2009 outbreak, which presented its first 
epidemic wave around August–October 2008 and a full epidemic 
wave started in November 2008 at the onset of the rainy season.           
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The association between rainfall and cholera outbreaks is well 
documented (Camacho et al., 2018; Hashizume et al., 2010; Luque 
Fernandez et al., 2009; Goel and Jiang, 2011; Rinaldo et al., 2012; 
Eisenberg et al., 2013). The 2018 cholera outbreak had a distinct 
spatial pattern, with the emergence of the outbreak being located 
in Harare, where most of the reported cases were clustered, and 
started expanding to neighborhood districts and other parts of the 
country (Figure 1). Budiriro and Glen View suburbs in Harare were 
identified as the epicenter of the cholera outbreak (Figure 1). 
Zimbabwe has gone through a debilitating political, social and 
economic crisis, which began in the last two decades. Due to 
declining funding over the years, the Zimbabwe National Water 
Authority has been unable to invest in maintaining critical 
infrastructure for water and sewerage reticulation, resulting in 
frequent bursts and collapse of the systems (MoHCC, 2018). The 
effects of the crisis have been felt in the healthcare system, as 
evidenced by a marked decline in health financing by the              ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND 
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Figure 1. Map showing Budiriro andGlen View (the epicenter of the outbreak) and other regions reporting cholera by 18 September 2018 (MoHCC, 2018a).Mapswere created 
using ArcGIS1 by ESRI version 10.5 (http://www.esri.com) (ESRI, 2004).       
       
          
        
       
       
       
        
         
         
        
        
       
      
       
        
    
      
       
        
       
             
            
            
            
             
           
            
            
       
        
          
government, inadequate or non-availability of essential medicines 
and consumables, high attrition rates, and poorly motivated 
human resources for health (Cuneo et al., 2017). The availability of 
portable water and adoption of proper hygiene practices are 
essential for long-term cholera prevention, control and eradica-
tion. Unfortunately, in the timescale of cholera epidemics, 
improving infrastructure for clean water and adequate sanitation 
is impossible, particularly in a country recovering from economic 
crisis. Antibiotics for treating cholera are recommended for use in 
severe cases and their use for mass administration against cholera 
infection is strongly discouraged by theWorld Health Organization 
(WHO), as they could contribute to antimicrobial resistance (WHO, 
2018a). Recent findings of significant resistance to first-line 
commonly available antibiotics by the National Microbiology 
Reference Laboratory has raised concerns, particularly given the 
well-documented resistance to the typhoid outbreak inHarare that 
started in 2016 (MoHCC, 2018). 
The current-generation oral cholera vaccine (OCV) have 
renewed interests in using vaccination for cholera prevention 
and control (Shin et al., 2011), with overwhelming evidence 
supporting their effectiveness in cholera endemic settings (Lucas 
et al., 2005; Sur et al., 2009; Thiem et al., 2006; Clemens et al., 
1990; Clemens et al., 1988Lucas et al., 2005; Sur et al., 2009; Thiem 
et al., 2006; Clemens et al., 1990; Clemens et al., 1988Lucas et al., 
2005; Sur et al., 2009; Thiem et al., 2006; Clemens et al., 1990; 
Clemens et al., 1988Lucas et al., 2005; Sur et al., 2009; Thiem et al., 
2006; Clemens et al., 1990; Clemens et al., 1988Lucas et al., 2005; 
Sur et al., 2009; Thiem et al., 2006; Clemens et al., 1990; Clemens 
et al., 1988). In recent years, theWHO has recommended the use of 
cholera vaccines in endemic settings and pre-emptively during 
epidemic and outbreak settings, and established a global stockpile 
of oral cholera vaccine (Martin et al., 2012; WHO, 2010). Some            
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OCVs such as Vaxchora have been reported to reduce the chance of 
severe diarrhea in humans by 90% at 10 days after vaccination and 
by 80% at 3 months after vaccination (PVOCVA, 2018). Currently, 
WHO requalified safe and effective OCVs are available on the 
market at a modest cost ($1.30–1.85 per dose) (PVOCVA, 2018; 
Kirpich et al., 2017; Ivers, 2017). Moreover, some of the OCVs 
available on themarket remain stable at 37 C for 30 days, avoiding 
waste and a stringent cold chain (Kirpich et al., 2017). TheWHOhas 
put in place the Global Task Force on Cholera Control (GTFCC) 
(WHO, 2018b) to support countries to implement effective cholera 
control programs. Zimbabwe's Ministry of Health and Child Care 
(MoHCC) endorses the new global strategy by the GTFCC ‘Ending 
Cholera—A Global Roadmap to 2030’ (Ending cholera, 2018). This 
operationalizes the new global strategy for cholera control at a 
country level and provides a concrete path towards a cholera-free 
world. The GTFCC processes requests from Ministries of Health to 
use OCV in highly endemic cholera settings (hotspots) with the 
goal of providing equitable access for the populations most 
exposed to the risk of cholera. 
It is important to understand the utility of OCV for this 
outbreak, for which Zimbabwe made the first attempt to 
implement reactive mass vaccination in some areas (MoHCC, 
2018b). Mathematical models provide a valuable tool for this 
purpose and there is an increasing appreciation of mathematical 
models in informing public health policy in the emergency 
situation of an initial cholera epidemic (Mukandavire et al., 
2013; Mukandavire and Morris, 2015). OCV mass vaccination 
campaigns in Zimbabwe were conducted in four high-density 
suburbs in Harare (Budiriro, Glen Norah, Glen View, and Mbare) 
and then moved to other areas (MoHCC, 2018b). This study used a 
previously developed Zimbabwe cholera model to estimate the 
basic reproductive number of the epicenter of the outbreak 
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Figure 2. Cholera model fitting for the cumulative cholera cases where the orange 
and green regions are the 50% and 95% CrIs, the dashed brown line is the median 
model projection, and the blue circlemarks are the reported data for the cumulative 
number of cholera cases in Budiriro and Glen View.         
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(Budiriro and Glen View) and make public health recommenda-
tions on the usefulness of OCV in controlling the outbreak. 
Methods 
This study used a model that was developed for the 2008–2009 
cholera outbreak in Zimbabwe (Mukandavire et al., 2011; Mukan-
davire andMorris, 2015). The cholera compartmentalmodel divides 
thehumanpopulationofdensityN into susceptibles S, infected I and 
recovered R. The concentration of Vibrios in contaminated water is 
denoted by B. In the model, the susceptible individuals acquire 
cholera infection either by ingesting environmental Vibrios from 
contaminated aquatic reservoirs (a ‘slow’ transmission route 
requiring a higher infectious dose) or through close contact with 
infected humans associated with ingestion of ‘hyperinfectious’ 
Vibrios (Nelsonetal., 2009;Merrell et al., 2002) (a ‘fast’ transmission 
route related to the observed decrease in infectious dose seen 
among Vibrio cholerae (V. cholerae) within a matter of hours of 
passage in diarrheal stool) at daily per-capita rates 
beB le ¼ and lh ¼ bhI kþ B 
respectively, with the subscripts e and h denoting environment-to-
human and human-to-human transmission routes. The constant k 
is a shape parameter that determines the human infectious dose: 
when B equals k the probability of ingestion resulting in human 
disease is 0.5. Parameters βe and βh are rates of exposure to Vibrios 
from the contaminated environment and through human-to-
human interaction, respectively. Infected individuals recover from 
infection at a rate g . Cholera infected individuals contribute to V. 
cholerae in the aquatic environment at a daily rate χ and Vibrios 
have a net death rate d in the environment. Readers interested in 
the mathematical properties of the model should refer to 
(Mukandavire et al., 2011). The resulting model as a system of 
differential equations is as follows: 
dS B ¼ mN beS bhSI mS;dt kþ B 
dI B ¼ b S þ bhSI ðg þmÞI;edt kþ B ð1Þ
dR ¼ gI mR;
dt 
dB ¼ xI dB:
dt 
A Markov chain Monte Carlo (MCMC) based on a Bayesian 
framework (in R FME package (Soetaert and Petzoldt, 2010)) was 
used to fit the Zimbabwe cholera model to aggregated reported 
cholera cases for Budiriro and Glen View (the epicenter of the 
outbreak) to estimate the basic reproductive number and the 
vaccination coverage required to contain the epidemic. We used 
data on reported cholera cases published by the City of Harare, 
which covered the period from 1 September to 10 September 2018 
(CHHD, 2018). Similar to Haiti, these data may well be under-
estimates because of the weak health system in Zimbabwe. 
However, despite data quality, this study presents the best 
estimate of the magnitude of the outbreak and potential vaccine 
coverages needed to contain the outbreak. In the fitting, βe and βh 
were estimated to match the reported cholera cases and the initial  
           
  
          
        
   
      
Table 1 
Estimates of R e , R h , R 0 and minimum vaccination coverages with 95% Crls, assu
Parameter description
Partial reproductive numbers due to ‘slow’ transmission through the environment, R
Partial reproductive numbers due to ‘fast’ human-to-human transmission, R h 
Basic reproductive number, R 0 
Vaccination coverage resulting in disease control         
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infected populationwas also variedwith otherfixed parameters, as 
given in Supplementary Table 1. A Gaussian likelihood was used 
to draw model parameter posteriors assuming uniform 
non-informative priors, while the variances were regarded as 
nuisance parameters. TheMCMC chainwas generated with at least 
100,000 runs for the final fitting excluding the burn-in period. 
Chain convergence was examined visually and using the Coda R 
package. Extended runs were carried out in cases in which 
convergence was not evident. Uncertainty of each estimated 
parameter was evaluated by analyzing the MCMC chains and 
calculating the 2.5% and 97.5% quantiles to give the 95% credible 
interval (CrI). 
The basic reproductive number ðR 0Þ is defined as ameasure of the 
average number of secondary cases generated by a primary case. 
Understanding its magnitude and variation can help to identify 
cholera ‘hot spots’ and design targeted surveillance programs. The 
two transmission routes of cholera are quantitatively described by 
partial reproductive numbers, R h and R e that describe new cases 
that arise from either the fast human-to-human or the slower 
environment-to-human transmission routes, respectively. The 
mathematical expressions of R 0, R h and R e are given in 
Supplementarymaterial. The correspondingminimumvaccination 
coverage (c) for a cholera vaccinewith 78% efficacy for the Budiriro 
and Glen View outbreak was based on a formula in (Dietz, 1993) 
(and was applied elsewhere (Mukandavire et al., 2011)), 
11 R 0c ð2Þ
1 ð1 rÞð1 sÞ 
where r is the fraction of the vaccinated population who are 
completely immunized and s is the proportional reduction of the 
susceptibility for those partially immunized. 
Results 
Figure 2 shows fitted aggregated cholera cases for Budiriro and 
Glen View. Table 1 provides estimates of the basic reproductive     
   
 
 
 
 
ming a 78% vaccine efficacy. 
Estimated values (95% Crls) 
 e 0.15 (0.122–0.19) 
1.67 (1.41–1.92) 
1.82 (1.53–2.11) 
58% (45–68%) 
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number ðR 0Þ and partial reproductive numbers due to ‘fast’ 
human-to-human transmission ðR hÞ and ‘slow’ transmission 
through the environment ðR eÞ, and corresponding minimum 
OCV coverage that would be required to control the disease in 
Budiriro and Glen View when using vaccine with 78% efficacy 
(Lucas et al., 2005). 
Using estimates of R 0, sensitivity analysis of cholera vaccine 
efficacy was carried out to explore possible scenarios that may 
arise from using different types of vaccines by considering an 
efficacy range of 50–100%. The results suggest that a cholera 
vaccine with 55% efficacy (see Figure 3) is sufficient to contain the 
cholera outbreak but requires higher vaccination coverage 75% 
(95% Crl 58–88%). The required vaccination coverage for epidemic 
control decreases with increase in efficacy, with a vaccine of 100% 
efficacy requiring 45% (95% Crl 35–53%) coverage. However, most 
of the new-generation OCVs have shown efficacy of >65% (Lucas 
et al., 2005; Sur et al., 2009; Thiem et al., 2006; Clemens et al., 1990 
Lucas et al., 2005; Sur et al., 2009; Thiem et al., 2006; Clemens 
et al., 1990Lucas et al., 2005; Sur et al., 2009; Thiem et al., 2006; 
Clemens et al., 1990Lucas et al., 2005; Sur et al., 2009; Thiem et al., 
2006; Clemens et al., 1990) for periods sufficient to control 
outbreaks. 
Discussion 
The cholera outbreak, which started in the capital, Harare, and 
rapidly spread to other districts (MoHCC, 2018b) (see Figure 1) 
presented a short window in which to consider targeted cholera 
vaccination in Zimbabwe. This quantity of R 0 > 1 clearly showed 
that this outbreak had the potential to spread and spill over to 
other areas. The current results suggest that a cholera vaccine of 
55% would have been sufficient to contain the Budiriro and Glen 
View outbreak, although at a higher vaccination coverage (see 
Figure 3). However, it is noted that vaccination coverage 
significantly decreases for higher vaccine efficacy, suggesting that 
a vaccine with higher efficacy would be preferable when 
considering vaccination in Zimbabwe. Thus, the Euvichol Plus 
OCV, which was administered a few weeks after the outbreak 
(MoHCC, 2018b) with sustained protection of >60% for at least 3 
years after two doses (WHO, 2017), could have contained the 
outbreak if it had been timeously implemented and the desired 
coverage had been achieved. Unfortunately, data were unavailable 
to assess the impact of OVC in vaccinated areas usingmathematical 
models.          
               
     
Figure 3. Sensitivity analysis plot showing different vaccination coverages for 
different OCV efficacy. The blue and dark blue regions are the 50% and 95% CrIs and 
the red line is the median.         
        
           
        
            
         
            
         
         
          
         
          
          
         
         
        
       
         
         
            
       
       
        
    
       
       
         
           
          
         
          
        
      
      
       
        
      
        
       
          
        
 
     
         
         
        
        
           
       
       
          
       
         
        
  
         
         
            
            
           
         
       
        
         
        
      
A previous study for the 2008–2009 cholera outbreak in 
Zimbabwe estimated the required OCV coverages to contain the 
epidemic to be in the range of 13–82% in 10 provinces (Mukandavire 
et al., 2011; Mukandavire and Morris, 2015) (assuming vaccine 
efficacy of 78%). Similar to this study (see Figure 3), analysis of the 
2008–2009 cholera in Zimbabwe at provincial level showed that a 
vaccineof at least 65% efficacywould be able to control the epidemic 
in the entire country (see Supplementary Table 2). Similar results 
were also reported for the Haiti outbreak, with OCV coverages 
ranging from7–80% in all 10 departments (Mukandavire et al., 2013) 
and65%vaccineefficacywassufficient fordiseasecontrol.Estimated 
R 0 values for Haiti were very similar to those for Zimbabwe. A 
similarmodeling study on cholera in theOuest Department of Haiti 
demonstrated that a vaccine of at least 60% can successfully 
eliminate cholera within a few years (PVOCVA, 2018). However, in 
this study and previous studies (Mukandavire et al., 2011; 
Mukandavire et al., 2013) vaccination coverage estimates were 
based on direct vaccine protection and would potentially reduce if 
herd protection of cholera vaccines was taken into account (Ali 
et al., 2005). In the context of the Budiriro and Glen View cholera 
outbreak, the required vaccination coverage needed to achieve 
outbreak control could be further reduced with population 
immunity (Nelson et al., 2009) from recent sporadic cholera 
outbreaks (McAteer et al., 2018). 
Studies on cholera vaccination strategies suggest that ring 
vaccination deployed in the most affected geographical areas 
targeting individuals at highest risk of infection could reduce the 
number of doses needed to control the disease (Ali et al., 2016; 
Deen and von Seidlein, 2018; Azman et al., 2018). Recent studies 
have also shown that reactive vaccination campaigns using a single 
dose of OCV may be more cost-effective than a standard two-dose 
campaign when vaccine supplies are limited, and it reduces 
logistical challenges associated with vaccination campaigns in 
resource-constrained settings (Ciglenecki et al., 2018). Using 
spatially targeted ring vaccination and a single-dose vaccination 
approach could have been an important vaccination strategy in 
Zimbabwe, considering limited OCV supply (500,000 doses 
(MoHCC, 2018b; Muvishi, 2018)) and timing (the rainy season 
was approaching). Nevertheless, if data were available, actual 
outcomes of the mass vaccination could have been used to assess 
the value of future vaccination campaigns and strategies using 
mathematical models. 
Ciprofloxacin, tetracycline and Rocephin (ceftriaxone) resis-
tance was confirmed in the 2018 cholera outbreak in Zimbabwe 
(Mavhunga, 2018). There was a significant challenge as to which 
drug to give to patients, considering that azithromycin was 
unavailable in health facilities (Mavhunga, 2018). The WHO called 
for the review of the vaccine used in Zimbabwe due to multidrug 
resistance (RCV, 2018). Additionally, the substantial structural and 
operational challenges facing water and sewerage systems in 
Budiriro and Glen View could not be addressed and resulted in 
communities spending many hours without drinking water and 
long delays in repair of sewer blockages. This makes targeted 
cholera vaccination a very viable option for controlling cholera 
outbreaks in Zimbabwe. 
This study had some limitations. The estimate of R 0 was based 
on available data and this estimate could have possibly changed 
depending on the quality of the data from the start of the epidemic 
and the resolution of the modeling. It is noted that there was no 
separate data on reported cases for Budiriro and Glen View, as this 
would have been important in modeling the dynamics of the 
cholera outbreaks of the two suburbs individually. However, 
estimates of R 0 and the required vaccination coverage to contain 
the outbreak in the two suburbs are important in understanding 
the magnitude of the cholera outbreaks in Zimbabwe. As 
Zimbabwe has now embraced cholera vaccination (MoHCC, 
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2018b), these numbers may guide public health officials on 
expected vaccination coverages to contain future outbreaks. 
Currently in Zimbabwe, as in Haiti initially, there is a lack of 
understanding on the role of cholera vaccines in outbreak control 
because of limited experience in using OCVs in outbreak settings 
(Kirpich et al., 2017). In light of the current lack of extensive public 
health resources and the absence of a robust long-term cholera 
control strategy, this work highlights the key role that cholera 
vaccines will play in the short-term relief and stemming cholera 
tides. However, the potential public health benefits of widespread 
or targeted vaccination programs in a humanitarian emergency 
need to be carefully balanced against the potential ethical issues 
that may arise (Moodley et al., 2013; Stop Cholera, 2018). 
Nonetheless, to achieve optimal protection of the population at 
risk, OCVs should be integrated with water, sanitation and hygiene 
activities to permanently decrease the risk of transmission from 
environmental sources. 
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